image
mobile_image
headline
I take the TUKYSA® (tucatinib) regimen* for me, and them
content
*TUKYSA regimen: TUKYSA, trastuzumab
Not real patients.
Not real patients.
image
headline
What is TUKYSA?
subheadline
TUKYSA is a targeted oral treatment taken as part of a regimen, which includes another medicine called trastuzumab
content
TUKYSA is approved for adults with RAS wild-type human epidermal growth factor receptor-2 (HER2) positive colorectal cancer that has spread to other parts of the body (metastatic), or cannot be removed by surgery, and who have received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and it did not work or is no longer working.
This use is approved based on a clinical study that measured how many patients had a tumor response and how long that response lasted. Studies are ongoing to confirm the benefit of TUKYSA for this use.
It is not known if TUKYSA is safe and effective in children.
This use is approved based on a clinical study that measured how many patients had a tumor response and how long that response lasted. Studies are ongoing to confirm the benefit of TUKYSA for this use.
It is not known if TUKYSA is safe and effective in children.
headline
Know your biomarkers. Know your options.
icon
headline
What are biomarkers?
content
There are different types of colorectal cancer. Each type has different biomarkers. Some biomarkers can be proteins found in cancer cells. They are identified by testing tumor tissue.
Proteins are substances that help the cells in the body work.
icon
headline
What is the RAS biomarker?
content
Like HER2, RAS is a biomarker.
Sometimes RAS has a defect (also called a mutation) and sometimes it does not. When RAS does not have a defect, it is called RAS wild-type (RAS WT).
To be eligible for TUKYSA, you must have mCRC tumors that are both RAS wild-type and HER2+.
image
headline
What is the HER2 biomarker?
content
HER2 is a protein. In healthy cells, HER2 tells cells to grow and multiply at a normal rate.
Some cancer cells have too many HER2 proteins (HER2+). Having a lot of HER2 can tell cancer cells to grow and multiply quickly.
Some cancer cells have too many HER2 proteins (HER2+). Having a lot of HER2 can tell cancer cells to grow and multiply quickly.
image
headline
Target HER2 from the inside out
content
TUKYSA and trastuzumab are not chemotherapy.
Both medicines are designed to target HER2, but they do it in different ways. More than either therapy alone, TUKYSA and trastuzumab in combination may work together to more completely block the signal that tells cancer cells to grow.
HER2 is also found on normal cells. Therapies like TUKYSA that target HER2 can affect normal cells and cause side effects, some of which may be serious.
Both medicines are designed to target HER2, but they do it in different ways. More than either therapy alone, TUKYSA and trastuzumab in combination may work together to more completely block the signal that tells cancer cells to grow.
HER2 is also found on normal cells. Therapies like TUKYSA that target HER2 can affect normal cells and cause side effects, some of which may be serious.
buttons